Selinexor plus low-dose steroid for hard-to-treat myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 2 trial tests selinexor (a targeted anti-cancer medicine) plus low-dose dexamethasone to treat multiple myeloma that has not responded to many prior treatments. It compares selinexor combinations depending on what medicines you’ve already had, aiming to reduce myeloma activity and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and able to sign the consent form.
- You must have measurable multiple myeloma based on blood or urine “M protein” levels or abnormal free light chains.
- Your myeloma must match one of the trial’s treatment-history groups (how many prior therapies you had and which drug types you failed).
- Your body function tests must be adequate (kidney, liver, blood counts) and you can still tolerate study treatment.
- Your energy level score must be 0 to 2 (ECOG).
- If you can become pregnant, you must use two reliable birth-control methods and have a negative pregnancy test; men must also use protection if partnered with someone who could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a three-drug combination (selinexor, ruxolitinib, and methylprednisolone) for people with multiple myeloma that has come back or stopped responding after at least three prior treatments. The goal is to see if this new combination can help control the cancer.
This study tests the drug selinexor in combination with a bispecific antibody for multiple myeloma that has already been treated with at least 4 prior therapies. The goal is to see if the combination is safe and effective for patients whose disease has returned or hasn’t responded to previous treatments.
This trial tests a new drug called selinexor (KPT-330) combined with various standard treatments for patients whose multiple myeloma has come back or stopped responding to therapy. The goal is to see if adding selinexor helps control the cancer better than current options, and to find the safest dose for different drug pairings.
This early-phase study tests whether selinexor combined with VRd (bortezomib, lenalidomide, and dexamethasone) can improve outcomes for people with high-risk, newly diagnosed multiple myeloma. You may be a candidate if you have certain lab/genetic signs of “high-risk” disease and haven’t had prior myeloma treatment.
This trial studies a combination of selinexor, venetoclax, and dexamethasone to treat multiple myeloma that has returned or is resistant to prior treatments. It may help shrink the myeloma and improve disease control in people with a specific myeloma genetic marker (t(11;14)).
This trial tests a combination of four drugs (selinexor, carfilzomib, isatuximab, and dexamethasone) in patients whose multiple myeloma has come back or stopped responding to prior treatment. The goal is to see if this combination can shrink the cancer and help patients whose disease has high-risk features, like certain chromosome changes.
Hear when a new Multiple Myeloma, Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.